Retained Earnings (Accumulated Deficit) of eFFECTOR Therapeutics, Inc. from 31 Dec 2020 to 31 Mar 2024

Taxonomy & unit: us-gaap: USD
Description: The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary: eFFECTOR Therapeutics, Inc. quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Dec 2020 to 31 Mar 2024.
eFFECTOR Therapeutics, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending 31 Mar 2024 was $188,211,000, a 23% decline year-over-year.
Source SEC data: View on sec.gov

Retained Earnings (Accumulated Deficit), Quarterly (USD)

Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

eFFECTOR Therapeutics, Inc. Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q1 2024	$188,211,000	-$34,631,000	-23%	31 Mar 2024	10-Q	09 May 2024	2024	Q1
Q4 2023	$179,377,000	-$35,811,000	-25%	31 Dec 2023	10-Q	09 May 2024	2024	Q1
Q3 2023	$170,247,000	-$35,941,000	-27%	30 Sep 2023	10-Q	13 Nov 2023	2023	Q3
Q2 2023	$161,944,000	-$37,197,000	-30%	30 Jun 2023	10-Q	08 Aug 2023	2023	Q2
Q1 2023	$153,580,000	-$35,748,000	-30%	31 Mar 2023	10-Q	09 May 2023	2023	Q1
Q4 2022	$143,566,000	-$22,665,000	-19%	31 Dec 2022	10-K	26 Mar 2024	2023	FY
Q3 2022	$134,306,000	+$5,644,000	+4%	30 Sep 2022	10-Q	07 Nov 2022	2022	Q3
Q2 2022	$124,747,000	+$24,082,000	+16%	30 Jun 2022	10-Q	09 Aug 2022	2022	Q2
Q1 2022	$117,832,000	-$117,878,831	-251711%	31 Mar 2022	10-Q	10 May 2022	2022	Q1
Q4 2021	$120,901,000	+$15,798,000	+12%	31 Dec 2021	10-K	08 Mar 2023	2022	FY
Q3 2021	$139,950,000			30 Sep 2021	10-Q	08 Nov 2021	2021	Q3
Q2 2021	$148,829,000			30 Jun 2021	8-K	31 Aug 2021
Q1 2021	$46,831^*			31 Mar 2021	10-Q	03 Jun 2021	2021	Q1
Q4 2020	$136,699,000			31 Dec 2020	10-K	16 Mar 2022	2021	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.